Analyst Price Target is $5.00
▲ +653.01% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Verastem in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 653.01% upside from the last price of $0.66.
Current Consensus is
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Verastem. This Buy consensus rating has held steady for over two years.
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
Read More